Jeremy M. Lowen

Jeremy M. Lowen

Auto-generated profile, based on publicly available information

Jeremy M. Lowen

Department of Orthopaedic Surgery UC Davis Health Sacramento CA 95817 USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Biomaterials
Verified
Journal Article
Closed access
DGDrew E. Glaser
Drew E. Glaser
MCMatthew B. Curtis
Matthew B. Curtis
PSPeter A. Sariano
Peter A. Sariano
ZRZachary A. Rollins
Zachary A. Rollins
BSBhupinder S. Shergill
Bhupinder S. Shergill
SGSteven C. George
Steven C. George

8 February 2023 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
JLJeremy M. Lowen
Jeremy M. Lowen
GBGabriella C. Bond
Gabriella C. Bond
KGKatherine H. Griffin
Katherine H. Griffin
NSNathan K. Shimamoto
Nathan K. Shimamoto
VTVictoria L. Thai
Victoria L. Thai
JLJ. Kent Leach
J. Kent Leach

31 October 2022 in Acta Biomaterialia
Verified
Journal Article
Open access
MGMarissa A. Gionet-Gonzales
Marissa A. Gionet-Gonzales
RGRobert C.H. Gresham
Robert C.H. Gresham
KGKatherine H. Griffin
Katherine H. Griffin
ACAlena Casella
Alena Casella
RWRoss P. Wohlgemuth
Ross P. Wohlgemuth
JLJ. Kent Leach
J. Kent Leach
The therapeutic efficacy of mesenchymal stromal cells (MSCs) for tissue regeneration is critically linked to the potency of the complex mixture of growth factors, cytokines, exosomes, and other biological cues that they secrete. The duration of cell-based approaches is limited by rapid loss of cells upon implantation, motivating the need to prolong cell viability and extend the therapeutic influence of the secretome. We and others demonstrated that the secretome is upregulated when MSCs are formed into spheroids. Although the efficacy of the MSC secretome has been characterized in the literature, no studies have reported the therapeutic benefit of in situ sequestration of the secretome within a wound site using engineered biomaterials. We previously demonstrated the capacity of sulfated alginate hydrogels to sequester components of the MSC secretome for prolonged presentation in vitro, yet the efficacy of this platform has not been evaluated in vivo. In this study, we used sulfated alginate hydrogels loaded with MSC spheroids to aid in the regeneration of a rat muscle crush injury. We hypothesized that the use of sulfated alginate to bind therapeutically relevant growth factors from the MSC spheroid secretome would enhance muscle regeneration by recruiting host cells into the tissue site. The combination of sulfated alginate and MSC spheroids resulted in decreased collagen deposition, improved myogenic marker expression, and increased neuromuscular junctions 2 weeks after injury. These data indicate that MSC spheroids delivered in sulfated alginate represent a promising approach for decreased fibrosis and increased functional regeneration of muscle. STATEMENT OF SIGNIFICANCE: The therapeutic efficacy of mesenchymal stromal cells (MSCs) for tissue regeneration is attributed to the complex diversity of the secretome. Cell-based approaches are limited by rapid cell death, motivating the need to extend the availability of the secretome. We previously demonstrated that sulfated alginate hydrogels sequester components of the MSC secretome for prolonged presentation in vitro, yet no studies have reported the in situ sequestration of the secretome. Herein, we transplanted MSC spheroids in sulfated alginate hydrogels to promote muscle regeneration. MSC spheroids in sulfated alginate decreased collagen deposition, improved myogenic marker expression, and increased neuromuscular junctions. These data indicate that MSC spheroids delivered in sulfated alginate represent a promising approach for decreasing fibrosis and increasing functional muscle regeneration.